AI Market Mood: Stock Dashboard
SMMT
Fundamental
Company: Summit Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -1.44
Insider Own: 86.17%
Shs Outstand: 775.37M
Perf Week: 12.28%
Market Cap: 14.43B
Forward P/E: -
EPS next Y: -1.16
Insider Trans: 0.09%
Shs Float: 102.98M
Perf Month: 26.01%
Enterprise Value: 13.73B
PEG: -
EPS next Q: -0.26
Inst Own: 15.84%
Short Float: 35.07%
Perf Quarter: 10.81%
Income: -1.08B
P/S: -
EPS this Y: 19.22%
Inst Trans: 11.85%
Short Ratio: 13.34
Perf Half Y: -5.42%
Sales: 0.00M
P/B: 22.81
EPS next Y Percentage: 0.63%
ROA: -181.94%
Short Interest: 36.12M
Perf YTD: 10.81%
Book/sh: 0.85
P/C: 20.21
EPS next 5Y: 44.49%
ROE: -206.10%
52W High: 36.91 -47.49%
Perf Year: -5.28%
Cash/sh: 0.96
P/FCF: -
EPS past 3/5Y: -52.45% -13.76%
ROIC: -159.62%
52W Low: 13.83 40.13%
Perf 3Y: 1007.43%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 7.11%
Volatility M: 5.73%
Perf 5Y: 215.64%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -369.70%
Oper. Margin: -
ATR (14): 1.04
Perf 10Y: 178.53%
Dividend Ex-Date: -
Quick Ratio: 9.87
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 68.51
Recom: 1.71
Dividend Gr. 3/5Y: - -
Current Ratio: 9.87
EPS Q/Q: -244.58%
SMA20: 17.16%
Beta: -1.38
Target Price: 29.79
Payout: -
Debt/Eq: 0.03
Sales Q/Q: -
SMA50: 21.90%
Rel Volume: 1.14
Prev Close: 18.92
Employees: 265
LT Debt/Eq: 0.03
Earnings: Feb 23 AMC
SMA200: -2.30%
Avg Volume: 2.71M
Price: 19.38
IPO: Mar 05, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: -274.68% -
Trades:
Volume: 3,076,795
Change: 2.43%
Technical:
Latest News:
Citigroup Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation very bullish
SMMT
Summary: Citigroup initiated coverage of Summit Therapeutics with a Buy recommendation, projecting a 53.67% upside potential. Various funds and institutions are increasing their positions, with a bullish sentiment indicated by the put/call ratio of 0.35.
Full article2024-05-08T17:42:16Z